170 related articles for article (PubMed ID: 21109385)
1. Life-threatening anaphylactoid shock caused by recombinant tissue plasminogen activator.
Wang CT; Lin FC; Khor GT; Chen CH; Huang P
Am J Emerg Med; 2012 Jan; 30(1):253.e1-2. PubMed ID: 21109385
[TBL] [Abstract][Full Text] [Related]
2. Anaphylactoid reaction to recombinant tissue plasminogen activator.
Krmpotic KR; Fernandes CM
Eur J Emerg Med; 2007 Feb; 14(1):60-1. PubMed ID: 17198333
[TBL] [Abstract][Full Text] [Related]
3. Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke.
Hill MD; Barber PA; Takahashi J; Demchuk AM; Feasby TE; Buchan AM
CMAJ; 2000 May; 162(9):1281-4. PubMed ID: 10813008
[TBL] [Abstract][Full Text] [Related]
4. [Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)].
Cannas S; De Leo A; Marzari A
G Ital Cardiol; 1997 Mar; 27(3):278-80. PubMed ID: 9244730
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial.
Zinkstok SM; Vermeulen M; Stam J; de Haan RJ; Roos YB
Cerebrovasc Dis; 2010; 29(1):79-81. PubMed ID: 19907167
[TBL] [Abstract][Full Text] [Related]
6. Drop of PT Quick percent value is associated with both symptomatic and asymptomatic intracranial hemorrhage in patients treated with rt-PA for acute ischemic stroke.
Alonso A; Dempfle CE; Szabo K; Zohsel K; Hennerici MG
Thromb Res; 2011 Jan; 127(1):65-6. PubMed ID: 20537372
[No Abstract] [Full Text] [Related]
7. Hemorrhagic complications of thrombolytic therapy.
Vujković Z; Racić D; Miljković S; Dajić V
Med Pregl; 2012; 65(1-2):9-12. PubMed ID: 22452232
[TBL] [Abstract][Full Text] [Related]
8. Comparison of acute nonthrombolytic and thrombolytic treatments in ischemic stroke patients 80 years or older.
Zacharatos H; Hassan AE; Vazquez G; Hussein HM; Rodriguez GJ; Suri MF; Lakshminarayan K; Ezzeddine MA; Qureshi AI
Am J Emerg Med; 2012 Jan; 30(1):158-64. PubMed ID: 21247724
[TBL] [Abstract][Full Text] [Related]
9. Anaphylactoid reaction during an infusion of recombinant tissue-type plasminogen activator for acute myocardial infarction.
Massel D; Gill JB; Cairns JA
Can J Cardiol; 1991 Sep; 7(7):298-302. PubMed ID: 1933636
[TBL] [Abstract][Full Text] [Related]
10. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? - The Calgary experience.
Simon JE; Sandler DL; Pexman JH; Hill MD; Buchan AM;
Age Ageing; 2004 Mar; 33(2):143-9. PubMed ID: 14960429
[TBL] [Abstract][Full Text] [Related]
11. Alteplase for acute ischemic stroke.
Gonzales NR; Grotta JC
Expert Rev Cardiovasc Ther; 2006 May; 4(3):301-18. PubMed ID: 16716092
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing early results and complication rates of the thrombolytic treatment of lower limb ischemia with recombinant tissue-type plasminogen activator.
Asciutto G; Geier B; Marpe B; Hummel T; Mumme A
Chir Ital; 2006; 58(5):597-604. PubMed ID: 17069188
[TBL] [Abstract][Full Text] [Related]
13. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
[TBL] [Abstract][Full Text] [Related]
14. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
Hermann A; Dzialowski I; Koch R; Gahn G
J Neurol Sci; 2009 Sep; 284(1-2):155-7. PubMed ID: 19473668
[TBL] [Abstract][Full Text] [Related]
15. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
[TBL] [Abstract][Full Text] [Related]
16. The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis.
Sobesky J; Frackowiak M; Zaro Weber O; Hahn M; Möller-Hartmann W; Rudolf J; Neveling M; Grond M; Schmulling S; Jacobs A; Heiss WD
Cerebrovasc Dis; 2007; 24(1):56-65. PubMed ID: 17519545
[TBL] [Abstract][Full Text] [Related]
17. Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis.
Bravo Y; Martí-Fàbregas J; Cocho D; Rodríguez-Yáñez M; Castellanos M; de la Ossa NP; Roquer J; Obach V; Maestre J; Martí-Vilalta JL
Cerebrovasc Dis; 2008; 26(2):126-33. PubMed ID: 18560215
[TBL] [Abstract][Full Text] [Related]
18. The molecular basis of thrombolysis and its clinical application in stroke.
Murray V; Norrving B; Sandercock PA; Terént A; Wardlaw JM; Wester P
J Intern Med; 2010 Feb; 267(2):191-208. PubMed ID: 20175866
[TBL] [Abstract][Full Text] [Related]
19. Thrombolysis and hyperacute reperfusion therapy for stroke in renal patients.
Hirano T
Contrib Nephrol; 2013; 179():110-8. PubMed ID: 23652454
[TBL] [Abstract][Full Text] [Related]
20. Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use.
Lin SY; Tang SC; Tsai LK; Yeh SJ; Hsiao YJ; Chen YW; Chen KH; Yip BS; Shen LJ; Wu FL; Jeng JS
Eur J Neurol; 2014 Oct; 21(10):1285-91. PubMed ID: 24909847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
